Cardiology
Cardio-oncology
Cardiovascular effects of cancer therapy
Emerging pathwayAlso known as: onco-cardiology, cancer cardiotoxicity, chemotherapy heart
979
Clinical questions
201
Evidence-backed
100
Claims analyzed
Cardiology
Cardiovascular effects of cancer therapy
Synthesized from 201 evidence-backed clinical questions linked to this topic — 34 supporting the intervention, 53 against the intervention, 7 still contested.
Does aspirin vs placebo improve outcomes in Malignant Neoplasms?
Low Certainty+ Favors benefitaspirin vs placebo · All-Cause Mortality
10 studies (3,518,238 patients) provide low-certainty evidence for benefit of aspirin for All-Cause Mortality in Malignant Neoplasms.
Does history of cancer vs placebo improve outcomes in Malignant Neoplasms?
Low Certainty− Favors harmhistory of cancer vs placebo
2 studies (3,420,385 patients) provide low-certainty evidence against benefit of history of cancer for the outcome in Malignant Neoplasms.
Does sglt2 inhibitors vs placebo improve outcomes in Malignant Neoplasms?
Low Certainty+ Favors benefitsglt2 inhibitors vs placebo
5 studies (2,804,050 patients) provide low-certainty evidence for benefit of sglt2 inhibitors for the outcome in Malignant Neoplasms.
Does immune checkpoint inhibitors vs placebo improve outcomes in Malignant Neoplasms?
Low Certainty− Favors harmimmune checkpoint inhibitors vs placebo
31 studies (526,448 patients) provide low-certainty evidence against benefit of immune checkpoint inhibitors for the outcome in Malignant Neoplasms.
Does apixaban vs placebo improve outcomes in Venous Thromboembolism?
Low Certainty+ Favors benefitapixaban vs placebo
13 studies (521,153 patients) provide low-certainty evidence for benefit of apixaban for the outcome in Venous Thromboembolism.
Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity?
Low Certainty+ Favors benefitimmune checkpoint inhibitors vs placebo · Cardiac Index
25 studies (460,637 patients) provide low-certainty evidence for benefit of immune checkpoint inhibitors for Cardiac Index in cancer therapy-related cardiovascular toxicity.
Does doxorubicin vs placebo improve outcomes in Cardiotoxicity?
Insufficient~ Mixed resultsdoxorubicin vs placebo · Cardiac Index
73 studies (500,645 patients) provide insufficient evidence with mixed findings regarding doxorubicin for Cardiac Index in Cardiotoxicity.
Does doxorubicin vs placebo improve outcomes in Cardiomyopathies?
Low Certainty− Favors harmdoxorubicin vs placebo
10 studies (40 patients) provide low-certainty evidence against benefit of doxorubicin for the outcome in Cardiomyopathies.
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity?
Low Certainty+ Favors benefitimmune checkpoint inhibitors vs placebo · Cardiac Index
Does anticoagulants vs placebo improve outcomes in Malignant Neoplasms?
Low Certainty+ Favors benefitanticoagulants vs placebo · Myocardial Infarction Hospitalization
The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer
European Journal of Cancer — Byrne J — Oct 2018
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial
Journal of the American Heart Association — Rüger A — Nov 2020
Are cardiac Magnetic Resonance Imaging and Radionuclide Ventriculography Good Options Against Echocardiography for Evaluation of Anthracycline Induced Chronic Cardiotoxicity in Childhood Cancer Survivors?
Pediatric Hematology and Oncology — Başar E — Feb 2014
In-Depth Insight Into the Mechanisms of Cardiac Dysfunction in Patients With Childhood Cancer After Anthracycline Treatment Using Layer-Specific Strain Analysis
Circulation Journal — Yazaki K — Nov 2017
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Cardio-oncology (also known as onco-cardiology, cancer cardiotoxicity, chemotherapy heart). Cardiovascular effects of cancer therapy
Synapse tracks 6 specific clinical questions in Cardio-oncology, each synthesized independently from its own trial evidence. They include: "Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity?"; "Does anticoagulants vs placebo improve outcomes in Malignant Neoplasms?"; "Does sodium-glucose cotransporter-2 inhibitors vs immune checkpoint inhibitors improve All-Cause Mortality in Malignant Neoplasms?"; "Does carvedilol vs doxorubicin improve Cardiac Index in Malignant neoplasm of breast?"; "Does candesartan vs doxorubicin improve Cardiac Index in Malignant neoplasm of breast?".
As of 2026-08-14, the scientific consensus on Cardio-oncology is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/cardio-oncology.
Deterministic synthesis from Synapse's enriched corpus — 131 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Cardio-oncology paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Cardio-oncology papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
Subclinical Anthracycline-Induced Cardiotoxicity in the Long-Term Follow-Up of Lymphoma Survivors: A Multi-Layer Speckle Tracking Analysis
Arquivos Brasileiros de Cardiologia — Kang Y — Jan 2018